Study of carbapenemase-producing E. coli bacteria in southern France
Part of Infections clinical trials.
This study looks at bacteria that are resistant to strong antibiotics called carbapenems. It does not require participants, as it examines bacteria samples already collected.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You do not need to do anything for this study.
- The study uses bacteria samples already collected.
- It focuses on a type of bacteria called E. coli that produces carbapenemase.
- The bacteria samples are from southern France.
- There are no extra steps for patients.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patients who have severe infections caused by carbapenem-resistant Enterobacterales (CRE), which are bacteria that are hard to treat because they resist many antibiotics. It will examine the germs and how patients respond to newer antibiotics that are specifically used for these tough infections.
This study looks at whether certain bacteria that carry ESBL enzymes are spreading between people. To join, you would need lab-confirmed evidence that you carry these bacteria based on routine samples taken during usual care.
This study looks at bacteria (including antibiotic-resistant germs) present when you are admitted to a hospital. It may help doctors understand how often these germs are carried and how to respond early to prevent spread.
This study collects and studies lab-detected germs in hospital patients that produce special enzymes making some antibiotics less effective. It helps researchers understand how these resistant germs spread over time in Switzerland.
This study looks at why some healthy people carry resistant bacteria in their gut (called ESBL-producing bacteria). Researchers will collect stool and urine samples and ask about your daily life to find possible risk factors. You won't receive any treatment, but your participation can help scientists understand how to prevent the spread of these bacteria.
This study looks at whether patients in the intensive care unit (ICU) carry certain hard-to-treat bacteria (carbapenem-resistant enterobacteriaceae, or CRE) in their gut. By finding out how common this is, doctors can better protect patients from infections.
Hear when a new Antibiotic Resistance trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.